Skyward Specialty Insurance Group Inc. SKWD 深 沪
等待开盘 12-24 09:30:00 美东时间
51.98
-0.110
-0.21%
华盛通- 最 高53.089
- 今 开52.14
- 成交量 22.56万股
- 最 低 51.40
- 昨 收 52.09
- 总市值 21.05亿
- 52周最高 65.05
- 市盈率 静 18.10
- 换手率 0.56%
- 52周最低 41.28
- 委 比 91.99%
- 总股本 4048.74万
- 历史最高 65.05
- 量 比 0.74
- 振 幅 3.24%
- 历史最低 17.50
- 每 手 1
- 风险率 5.02%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 高盛上调梅西百货目标价至22美元！ 摩根大通上调美国铝业公司目标价至45美元
今日重点评级关注：Stifel：维持X4 Pharmaceuticals"买入"评级，目标价从7.5美元升至10美元；花旗：维持UP Fintech Holding"买入"评级，目标价从17.4美元升至17.5美元
12-08 08:34
美股大行评级 | 潜在涨幅218.88%！Kyverna Therapeutics获摩根士丹利升目标价至25美元，维持"超配"评级
今日重点评级关注：摩根士丹利：维持Kyverna Therapeutics"超配"评级，目标价从20美元升至25美元；Maxim Group：维持Capricor Therapeutics"买入"评级，目标价从25美元升至50美元
12-05 08:35
Skyward Specialty Says Regulatory Authorities And Minority Shareholders Approve Acquisition Of Apollo Group Holdings; Transaction Expected To Close Early In Q1 2026
Skyward Specialty Insurance Group, Inc. (NASDAQ:SKWD) ("Skyward Specialty" or the "Company") today announced that it has secured the required regulatory approvals and approvals of the minority shareholders of its
12-04 05:33
美股大行评级 | 苹果、亚马逊、Cloudflare、西部数据、Twilio等获十多家机构集体上调目标价；杰富瑞首予Cloudflare"持有"评级，目标价250美元
今日重点评级关注：康托·菲茨杰拉德：维持Cabaletta Bio"超配"评级，目标价从15美元升至30美元；HC Wainwright & Co.：维持Invivyd"买入"评级，目标价从5美元升至10美元
11-03 20:20
美股大行评级 | 最高350美元！16家大行上调谷歌目标价！Meta遭12家大行下调目标价；潜在涨幅1456.29%！NRX Pharmaceuticals获Ascendiant Capital升目标价至47美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从46美元升至47美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从27美元升至31美元
10-31 10:25
Citizens Maintains Market Outperform on Skyward Specialty, Raises Price Target to $75
Citizens analyst Matthew J. Carletti maintains Skyward Specialty (NASDAQ:SKWD) with a Market Outperform and raises the price target from $70 to $75.
10-30 20:57
Earnings Scheduled For October 29, 2025
Companies Reporting Before The Bell • OppFi (NYSE:OPFI) is expected to report q...
10-29 19:11
美股大行评级 | 潜在涨幅4347.41%！Ascendiant Capital上调PAVmed目标价至20美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持PAVmed"买入"评级，目标价从19美元升至20美元；Ascendiant Capital：维持Plus Therapeutics"买入"评级，目标价从20.5美元升至21美元
10-07 15:04
Analyst Expectations For Skyward Specialty's Future
During the last three months, 4 analysts shared their evaluations of Skyward Sp...
10-06 21:01
Janney Montgomery Scott Initiates Coverage On Skyward Specialty with Buy Rating, Announces Price Target of $60
Janney Montgomery Scott analyst Robert Farnam initiates coverage on Skyward Specialty (NASDAQ:SKWD) with a Buy rating and announces Price Target of $60.
10-06 20:20
